Meeting
2016 ASCO Annual Meeting
A phase I window, dose escalating and safety trial of metformin in combination with induction chemotherapy in relapsed refractory acute lymphoblastic leukemia: Metformin with induction chemotherapy of vincristine, dexamethasone, doxorubicin, and PEG-asparaginase (VPLD).
Authors
Julio C. Barredo
University of Miami School of Medicine, Miami, FL
Julio C. Barredo , John M. Goldberg , Gregory Hale , Jonathan Benjamin Gill , Bhuvana Setty , Tiffany Smith , Jae K Lee , Damon R. Reed
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Leukemia/Lymphoma
Clinical Trial Registration Number
NCT01324180
Citation
J Clin Oncol 34, 2016 (suppl; abstr 10530)
DOI
10.1200/JCO.2016.34.15_suppl.10530
Abstract #
10530
Poster Bd #
221
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Phase I trial of lorlatinib in combination with topotecan/cyclophosphamide in children with ALK-driven refractory or relapsed neuroblastoma: A new approaches to neuroblastoma therapy consortium study.
First Author: Kelly C. Goldsmith
Poster
2018 ASCO Annual Meeting
Open-label, dose-escalation, phase 1 study of venetoclax in combination with navitoclax and chemotherapy in patients with relapsed acute lymphoblastic leukemia.
First Author: Thomas Alexander
Poster
2016 ASCO Annual Meeting
Phase I trial of the combination of selinexor (SEL), liposomal doxorubicin (DOX) and dexamethasone (Dex) for relapsed and refractory multiple myeloma (RRMM).
First Author: Rachid C. Baz
Poster
2023 ASCO Annual Meeting
The ELiPSE-1 study: A phase 1, multicenter, open-label study of CNTY-101 in subjects with relapsed or refractory CD19-positive B-cell malignancies.
First Author: Krish Patel